Inventor · disambiguated record
Ozlem Tureci
Also filed as: TUE RECI OEZLEM · TUERECI OEZLEM · TUERECI OZLEM · TUERECIOEZLEM
125 granted patents·51 pending applications·919 citations·filing 1997–2025
99Inventor score
Files withGANYMED PHARMACEUTICALS AG41SAHIN UGUR35BIONTECH AG28LUDWIG INST CANCER RES17ASTELLAS PHARMA INC16
Top patents by PatentIndex Score
176 records- 0198US7527933B2Genetic products differentially expressed in tumors and the use thereofGANYMED PHARMACEUTICALS AG·Filed 2003·Granted May 5, 2009·115 cites·5 claims
- 0296US10106800B2Modification of RNA, producing an increased transcript stability and translation efficiencyBIONTECH AG·Filed 2016·Granted Oct 23, 2018·18 cites·11 claims
- 0395US8946388B2Monoclonal antibodies for treatment of cancerSAHIN UGUR·Filed 2009·Granted Feb 3, 2015·41 cites·16 claims
- 0495US8425902B2Monoclonal antibodies against claudin-18 for treatment of cancerSAHIN UGUR·Filed 2008·Granted Apr 23, 2013·20 cites·3 claims
- 0595US8168427B2Monoclonal antibodies against claudin-18 for treatment of cancerSAHIN UGUR·Filed 2006·Granted May 1, 2012·47 cites·5 claims
- 0694US11547673B1Coronavirus vaccineBioNTech SE·Filed 2021·Granted Jan 10, 2023·12 cites·45 claims
- 0794US10117918B2Antigen-specific T cell receptors and T cell epitopesSAHIN UGUR·Filed 2016·Granted Nov 6, 2018·18 cites·13 claims
- 0894US9751934B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Sep 5, 2017·13 cites·20 claims
- 0994US9476055B2Modification of RNA, producing an increased transcript stability and translation efficiencySAHIN UGUR·Filed 2006·Granted Oct 25, 2016·29 cites·19 claims
- 1094US8637012B2Genetic products differentially expressed in tumors and the use thereofSAHIN UGUR·Filed 2011·Granted Jan 28, 2014·18 cites·9 claims
- 1194US8586047B2Genetic products differentially expressed in tumors and the use thereofSAHIN UGUR·Filed 2009·Granted Nov 19, 2013·20 cites·18 claims
- 1294US8088588B2Genetic products differentially expressed in tumors and the use of thereofSAHIN UGUR·Filed 2008·Granted Jan 3, 2012·17 cites·13 claims
- 1393US11859008B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS GMBH·Filed 2020·Granted Jan 2, 2024·2 cites·12 claims
- 1493US9718886B2Cancer therapy using CLDN6 target-directed antibodies in vivoSAHIN UGUR·Filed 2011·Granted Aug 1, 2017·13 cites·6 claims
- 1592US9487584B2Antibodies specific for claudin 6 (CLDN6)SAHIN UGUR·Filed 2010·Granted Nov 8, 2016·19 cites·20 claims
- 1692US9321842B2Antibodies for treatment of cancerSAHIN UGUR·Filed 2012·Granted Apr 26, 2016·14 cites·30 claims
- 1792US9267177B2Identification of tumor-associated cell surface antigens for diagnosis and therapyBIONTECH AG·Filed 2015·Granted Feb 23, 2016·6 cites·7 claims
- 1891US10813996B2Combination therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2018·Granted Oct 27, 2020·4 cites·18 claims
- 1991US9175088B2Identification of tumor-associated markers for diagnosing or monitoring ovarian cancerSAHIN UGUR·Filed 2010·Granted Nov 3, 2015·8 cites·14 claims
- 2091US7785801B2Identification of surface-associated antigens for tumor diagnosis and therapyGANYMED PHARMACEUTICALS AG·Filed 2005·Granted Aug 31, 2010·14 cites·4 claims
- 2190US10717780B2Agents for treatment of claudin expressing cancer diseasesBIONTECH AG·Filed 2018·Granted Jul 21, 2020·5 cites·12 claims
- 2290US10233253B2Antibodies for treatment of cancer expressing claudin 6GANYMED PHARMACEUTICALS AG·Filed 2016·Granted Mar 19, 2019·7 cites·16 claims
- 2390US9770487B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic adenocarcinomaGANYMED PHARMACEUTICALS AG·Filed 2014·Granted Sep 26, 2017·11 cites·30 claims
- 2490US9044382B2Genetic products differentially expressed in tumors and the use thereofTüreci Özlem·Filed 2005·Granted Jun 2, 2015·17 cites·7 claims
- 2590US6338947B1Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewithLUDWIG INST CANCER RES·Filed 2000·Granted Jan 15, 2002·33 cites·15 claims
- 2689US11925694B2Coronavirus vaccineBioNTech SE·Filed 2022·Granted Mar 12, 2024·1 cites·36 claims
- 2789US10053512B2Antibodies against claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2016·Granted Aug 21, 2018·6 cites·34 claims
- 2889US10017564B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 10, 2018·6 cites·21 claims
- 2989US9512232B2Antibodies against Claudin 18.2 useful in cancer diagnosisGANYMED PHARMACEUTICALS AG·Filed 2013·Granted Dec 6, 2016·9 cites·11 claims
- 3089US9212228B2Monoclonal antibodies against claudin-18 for treatment of cancerSAHIN UGUR·Filed 2012·Granted Dec 15, 2015·9 cites·42 claims
- 3188US10314890B2Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Granted Jun 11, 2019·5 cites·40 claims
- 3288US2024117022A1Monoclonal antibodies against claudin-18 for treatment of cancerASTELLAS PHARMA INC·Filed 2023·Application pending·0 cites
- 3387US10927413B2Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosisGANYMED PHARMACEUTICALS GMBH·Filed 2016·Granted Feb 23, 2021·3 cites·21 claims
- 3487US10738108B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2017·Granted Aug 11, 2020·2 cites·28 claims
- 3587US10137195B2Therapy involving antibodies against Claudin 18.2 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2014·Granted Nov 27, 2018·7 cites·19 claims
- 3687US9533043B2Identification of surface-associated antigens for tumor diagnosis and therapyBIONTECH AG·Filed 2013·Granted Jan 3, 2017·7 cites·5 claims
- 3787US9486519B2Use of FLT3 ligand for enhancing immune responses in RNA immunizationSAHIN UGUR·Filed 2009·Granted Nov 8, 2016·15 cites·6 claims
- 3887US8178653B2Recombinant vaccines and use thereofTUERECI OEZLEM·Filed 2004·Granted May 15, 2012·20 cites·4 claims
- 3987US2024309108A1Antibodies against claudin 18.2 useful in cancer diagnosisASTELLAS PHARMA INC·Filed 2024·Application pending·0 cites
- 4086US10604568B2Diagnosis and therapy of cancer involving cancer stem cellsBIONTECH AG·Filed 2014·Granted Mar 31, 2020·6 cites·10 claims
- 4186US9216218B2Monoclonal antibodies for treatment of cancerSAHIN UGUR·Filed 2011·Granted Dec 22, 2015·11 cites·6 claims
- 4286US9194004B2Identification of surface-associated antigens for tumor diagnosis and therapyBIONTECH AG·Filed 2013·Granted Nov 24, 2015·6 cites·4 claims
- 4386US9090940B2Identification of surface-associated antigens for tumor diagnosis and therapySAHIN UGUR·Filed 2006·Granted Jul 28, 2015·3 cites·11 claims
- 4486US6548064B1Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA moleculesLUDWIG INST CANCER RES·Filed 1999·Granted Apr 15, 2003·51 cites·6 claims
- 4586US2025242059A1Coronavirus vaccineBioNTech SE·Filed 2024·Application pending·0 cites
- 4685US11787862B2Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseasesBIONTECH AG·Filed 2017·Granted Oct 17, 2023·3 cites·32 claims
- 4785US10174104B2Monoclonal antibodies against claudin-18 for treatment of cancerGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Jan 8, 2019·3 cites·24 claims
- 4885US9775785B2Antibody to genetic products differentially expressed in tumors and the use thereofGANYMED PHARMACEUTICALS AG·Filed 2015·Granted Oct 3, 2017·5 cites·12 claims
- 4985US9499609B2Monoclonal antibodies against claudin-18 for treatment of cancerSAHIN UGUR·Filed 2011·Granted Nov 22, 2016·5 cites·21 claims
- 5085US8975375B2Identification of tumor-associated antigens for diagnosis and therapySAHIN UGUR·Filed 2011·Granted Mar 10, 2015·5 cites·15 claims
Showing the top 50 of 176 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →